T-cell changes after a short-term exposure to maraviroc in HIV-infected patients are related to antiviral activity

Journal of Infection

Volumn 64, Issue 4, 2012, Pages 417-423

  Pulido, Ildefonso ^a   Machmach, Kawthar ^a   Romero Sánchez, María C ^a   Genebat, Miguel ^a   Mendez Lagares, Gema ^a   Ruiz Mateos, Ezequiel ^a   Leal, Manuel ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

CCR5 antagonist; CD4 positive T lymphocytes; HIV; Maraviroc; Viral tropism

Indexed keywords

MARAVIROC;

ADULT; AGE DISTRIBUTION; ANTIVIRAL ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEPATITIS C; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; T LYMPHOCYTE; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYCLOHEXANES; FEMALE; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; RECEPTORS, CCR5; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES; TREATMENT OUTCOME; TRIAZOLES; VIRAL LOAD;

EID: 84858439283     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2011.12.017     Document Type: Article

References (16)

1. Soriano V., Perno C.F., Kaiser R., Calvez V., Gatell J.M., di Perri G., et al. When and how to use maraviroc in HIV-infected patients. AIDS 2009, 23:2377-2385.
2. Hammer S.M., Eron J.J., Reiss P., Schooley R.T., Thompson M.A., Walmsley S., et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008, 300:555-570.
3. Gulick R.M., Lalezari J., Goodrich J., Clumeck N., DeJesus E., Horban A., et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008, 359:1429-1441.
4. Cooper D.A., Heera J., Goodrich J., Tawadrous M., Saag M., Dejesus E., et al. Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. J Infect Dis 2010, 201:803-813.
5. + T-Cell restoration after 48 Weeks in the maraviroc treatment-experienced trials MOTIVATE 1 and 2. J Acquir Immune Defic Syndr 2010, 54:394-397.
6. Saag M., Goodrich J., Fätkenheuer G., Clotet B., Clumeck N., Sullivan J., et al. A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1. J Infect Dis 2009, 199:1638-1647.
7. Corbeau P., Reynes J. CCR5 antagonism in HIV infection: ways, effects, and side effects. AIDS 2009, 23:1931-1943.
8. Fätkenheuer G., Pozniak A.L., Johnson M.A., Plettenberg A., Staszewski S., Hoepelman A.I., et al. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med 2005, 11:1170-1172.
9. Genebat M., Ruiz-Mateos E., León J.A., González-Serna A., Pulido I., Rivas I. Correlation between the Trofile test and virological response to a short-term maraviroc exposure in HIV-infected patients. J Antimicrob Chemoter 2009, 64:845-849.
10. Ferrando-Martinez S., Ruiz-Mateos E., Leal M. CD27 and CCR7 expression on naive T cells, are both necessary?. Immunol Lett 2010, 127:157-158.
11. Madani N., Hubicki A.M., Perdigoto A.L., Springer M., Sodroski J. Inhibition of human immunodeficiency virus envelope glycoprotein-mediated single cell lysis by low-molecular-weight antagonists of viral entry. J Virol 2007, 81:532-538.
12. Stepanyuk O., Chiang T.S., Dever L.L., Paez S.L., Smith S.M., Perez G., et al. Impact of adding maraviroc to antiretroviral regimens in patients with full viral suppression but impaired CD4 recovery. AIDS 2009, 23:1911-1913.
13. + T cell response in a perinatally HIV-infected adolescent. AIDS 2011, 25:1243-1244.
14. von Andrian U.H., Mackay C.R. T-cell function and migration. Two sides of the same coin. N Engl J Med 2000, 343:1020-1034.
15. Pett S.L., Zaunders J., Bailey M., Murray J., MacRae K., Emery S., et al. A novel chemokine-receptor-5 (CCR5) blocker, SCH532706, has differential effects on CCR5+CD4+ and CCR5+CD8+ T cell numbers in chronic HIV infection. AIDS Res Hum Retroviruses 2010, 26:653-661.
16. Schürmann D., Fätkenheuer G., Reynes J., Michelet C., Raffi F., van Lier J., et al. Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults. AIDS 2007, 21:1293-1299.